Vyome Holdings, Inc. (NASDAQ:HIND) Sees Large Decrease in Short Interest

Vyome Holdings, Inc. (NASDAQ:HIND) saw a significant drop in short interest during the month of June. As of June 30th, there was short interest totaling 35,140 shares, a drop of 45.9% from the June 15th total of 64,989 shares. Approximately 0.7% of the company’s shares are sold short. Based on an average daily trading volume, of 20,610 shares, the days-to-cover ratio is currently 1.7 days.

Vyome Stock Down 1.8%

HIND traded down $0.04 during trading hours on Friday, reaching $2.15. 9,247 shares of the company’s stock traded hands, compared to its average volume of 407,451. The firm has a 50-day moving average price of $2.18 and a 200 day moving average price of $2.45. Vyome has a 52-week low of $1.75 and a 52-week high of $18.60. The firm has a market capitalization of $15.09 million, a PE ratio of -0.18 and a beta of 1.49.

Vyome (NASDAQ:HIND) last released its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter. The business had revenue of $0.03 million during the quarter. Equities analysts predict that Vyome will post -0.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Vyome stock. Millennium Management LLC acquired a new stake in Vyome Holdings, Inc. (NASDAQ:HIND) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 45,144 shares of the company’s stock, valued at approximately $155,000. Millennium Management LLC owned 0.80% of Vyome at the end of the most recent reporting period. Institutional investors own 22.06% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on HIND shares. Litchfield Hills Research initiated coverage on shares of Vyome in a research report on Monday, May 4th. They set a “buy” rating on the stock. Zacks Research raised shares of Vyome to a “hold” rating in a research note on Wednesday, May 6th. Finally, Weiss Ratings upgraded shares of Vyome from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Vyome currently has an average rating of “Hold” and a consensus target price of $15.00.

About Vyome

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.